Inventor · disambiguated record
Elena Feinstein
Also filed as: FEINSTEIN ELENA
78 granted patents·68 pending applications·917 citations·filing 1997–2024
99Inventor score
Files withQUARK PHARMACEUTICALS INC47FEINSTEIN ELENA36QUARK BIOTECH INC10NITTO DENKO CORP6AVKIN-NACHUM SHARON5
Top patents by PatentIndex Score
146 records- 0199US7626015B2Therapeutic uses of inhibitors of RTP801LQUARK PHARMACEUTICALS INC·Filed 2007·Granted Dec 1, 2009·113 cites·6 claims
- 0298US7741299B2Therapeutic uses of inhibitors of RTP801QUARK PHARMACEUTICALS INC·Filed 2005·Granted Jun 22, 2010·107 cites·12 claims
- 0397US7825099B2Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesQUARK PHARMACEUTICALS INC·Filed 2007·Granted Nov 2, 2010·24 cites·14 claims
- 0495US9932578B2Double-stranded oligonucleotide molecules to P53 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2013·Granted Apr 3, 2018·31 cites·9 claims
- 0595US8741867B2Retinoid-liposomes for treating fibrosisNIITSU YOSHIRO·Filed 2012·Granted Jun 3, 2014·34 cites·29 claims
- 0695US8664376B2Retinoid-liposomes for enhancing modulation of HSP47 expressionNIITSU YOSHIRO·Filed 2012·Granted Mar 4, 2014·30 cites·26 claims
- 0795US7910566B2Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNAQUARK PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·20 cites·5 claims
- 0894US6998232B1Methods of diagnosing bladder cancerQUARK BIOTECH INC·Filed 2001·Granted Feb 14, 2006·109 cites·7 claims
- 0993US10196637B2Retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2016·Granted Feb 5, 2019·7 cites·20 claims
- 1093US9206424B2Modulation of HSP47 expressionNITTO DENKO CORP·Filed 2014·Granted Dec 8, 2015·21 cites·33 claims
- 1193US7812002B2Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancerQUARK PHARMACEUTICALS INC·Filed 2008·Granted Oct 12, 2010·21 cites·24 claims
- 1292US9121020B2Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·20 cites·23 claims
- 1390US8710209B2Modulation of HSP47 expressionJIN XIAOMEI·Filed 2010·Granted Apr 29, 2014·22 cites·37 claims
- 1490US8017764B2Therapeutic uses of inhibitors of RTP801LQUARK PHARMACEUTICALS INC·Filed 2009·Granted Sep 13, 2011·10 cites·8 claims
- 1590US7842674B2Methods of treatment of acute renal failureQUARK PHARMACEUTICALS INC·Filed 2007·Granted Nov 30, 2010·14 cites·25 claims
- 1690US7259253B2Genes associated with mechanical stress, expression products therefrom, and uses thereofQUARK BIOTECH INC·Filed 2003·Granted Aug 21, 2007·57 cites·18 claims
- 1790US5968822APolynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cellsFiled 1997·Granted Oct 19, 1999·75 cites·30 claims
- 1889US9456984B2Method for treating fibrosis using siRNA and a retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2014·Granted Oct 4, 2016·10 cites·58 claims
- 1989US7872119B2Inhibitors of RTP801 and their use in disease treatmentQUARK PHARMACEUTICALS INC·Filed 2008·Granted Jan 18, 2011·11 cites·13 claims
- 2088US8614309B2Double-stranded RNA directed to CASP2 and methods of use thereofFEINSTEIN ELENA·Filed 2008·Granted Dec 24, 2013·11 cites·34 claims
- 2188US8404654B2Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesFEINSTEIN ELENA·Filed 2009·Granted Mar 26, 2013·3 cites·28 claims
- 2288US6960471B2Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cellsHADASIT MED RES SERVICE·Filed 2003·Granted Nov 1, 2005·11 cites·27 claims
- 2387US8309532B2Therapeutic uses of inhibitors of RTP801FEINSTEIN ELENA·Filed 2010·Granted Nov 13, 2012·7 cites·9 claims
- 2487US8148342B2Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesFEINSTEIN ELENA·Filed 2008·Granted Apr 3, 2012·9 cites·26 claims
- 2587US6790658B2Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cellsINSIGHT BIOPHARMACEUTICALS LTD·Filed 2001·Granted Sep 14, 2004·11 cites·31 claims
- 2686US10093923B2Modulation of HSP47 expressionNITTO DENKO CORP·Filed 2015·Granted Oct 9, 2018·5 cites·35 claims
- 2786US9446062B2Methods of treating ischemia-reperfusion injury with siRNAsQUARK PHARMACEUTICALS INC·Filed 2015·Granted Sep 20, 2016·4 cites·14 claims
- 2886US8785408B2Compositions and methods for reducing or protecting against delayed graft function (DGF)FEINSTEIN ELENA·Filed 2008·Granted Jul 22, 2014·11 cites·20 claims
- 2985US10195145B2Method for treating fibrosis using siRNA and a retinoid-lipid drug carrierNITTO DENKO CORP·Filed 2016·Granted Feb 5, 2019·4 cites·31 claims
- 3085US8278287B2siRNA compounds for inhibiting NRF2FEINSTEIN ELENA·Filed 2009·Granted Oct 2, 2012·5 cites·21 claims
- 3184US8067570B2Therapeutic uses of inhibitors of RTP801FEINSTEIN ELENA·Filed 2007·Granted Nov 29, 2011·6 cites·22 claims
- 3283US10183056B2Methods and compositions for the treatment of radiation-related disordersCLEVELAND BIOLABS INC·Filed 2015·Granted Jan 22, 2019·3 cites·13 claims
- 3382US10857200B2Methods and compositions for the treatment of radiation-related disordersCLEVELAND BIOLABS INC·Filed 2018·Granted Dec 8, 2020·1 cites·13 claims
- 3482US8444983B2Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseasesFEINSTEIN ELENA·Filed 2010·Granted May 21, 2013·4 cites·15 claims
- 3582US8410069B2Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancerFEINSTEIN ELENA·Filed 2010·Granted Apr 2, 2013·5 cites·26 claims
- 3682US8362229B2Tandem siRNASQUARK PHARMACEUTICALS INC·Filed 2007·Granted Jan 29, 2013·6 cites·25 claims
- 3781US9701961B2Methods for treating eye disordersQUARK PHARMACEUTICALS INC·Filed 2015·Granted Jul 11, 2017·3 cites·20 claims
- 3881US9056903B2Therapeutic uses of inhibitors of RTP801FEINSTEIN ELENA·Filed 2011·Granted Jun 16, 2015·4 cites·19 claims
- 3981US7524935B2Sequences characteristic of hypoxia-regulated gene transcriptionQUARK PHARMACEUTICALS INC·Filed 2006·Granted Apr 28, 2009·1 cites·10 claims
- 4080US9993567B2Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseasesQUARK PHARMACEUTICALS INC·Filed 2015·Granted Jun 12, 2018·2 cites·11 claims
- 4180US8614311B2RTP801L siRNA compounds and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2012·Granted Dec 24, 2013·2 cites·19 claims
- 4279US7074895B2Sequences characteristic of hypoxia-regulated gene transcriptionQUARK BIOTECH INC·Filed 2001·Granted Jul 11, 2006·3 cites·1 claims
- 4378US9222087B2Therapeutic uses of inhibitors of RTP801LFEINSTEIN ELENA·Filed 2013·Granted Dec 29, 2015·2 cites·7 claims
- 4477US8778904B2Methods and compositions for treating diseases, disorders or injury of the CNSFEINSTEIN ELENA·Filed 2010·Granted Jul 15, 2014·6 cites·20 claims
- 4576US9434946B2Combination therapy for treating hearing and balance disordersQUARK PHARMACEUTICALS INC·Filed 2015·Granted Sep 6, 2016·2 cites·17 claims
- 4676US8859751B2Oligonucleotide compounds comprising non-nucleotide overhangsAVKIN-NACHUM SHARON·Filed 2011·Granted Oct 14, 2014·3 cites·22 claims
- 4776US8637482B2Methods for treating chronic kidney diseaseFEINSTEIN ELENA·Filed 2010·Granted Jan 28, 2014·3 cites·15 claims
- 4876US8168607B2Methods of treating eye diseases in diabetic patientsFEINSTEIN ELENA·Filed 2010·Granted May 1, 2012·2 cites·10 claims
- 4976US7939652B2Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseasesQUARK PHARMACEUTICALS INC·Filed 2008·Granted May 10, 2011·2 cites·16 claims
- 5075US10421962B2Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereofQUARK PHARMACEUTICALS INC·Filed 2017·Granted Sep 24, 2019·1 cites·6 claims
Showing the top 50 of 146 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Elena Feinstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →